Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2020 – CLL: Wrap-Up
ASH 2020 – CLL: Wrap-Up
Lisocabtagene Maraleucel in High-Risk and Pretreated Patients with Relapsed or Refractory CLL
ASH 2020 – CLL: Wrap-Up
In pretreated, high-risk patients with relapsed or refractory chronic lymphocytic leukemia (CLL), treatment with lisocabtagene maraleucel (liso-cel) resulted in a high rate of undetectable minimal residual disease. Responses to treatment with liso-cel were rapid and durable, without late or delayed adverse events of concern.
Read More ›
LOXO-305 in Previously Treated CLL/SLL: Safety and Early Efficacy Data from the BRUIN Trial
ASH 2020 – CLL: Wrap-Up
The noncovalent BTK inhibitor LOXO-305 demonstrated promising efficacy in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). LOXO-305 was well-tolerated and active in patients following multiple prior lines of therapy, including patients with and without BTK
C481
mutations.
Read More ›
Safety and Efficacy of CD19-CAR T-Cells in Richter’s Transformation Following Targeted Therapy for CLL
ASH 2020 – CLL: Wrap-Up
Treatment with CD19-CAR T-cells in patients with chronic lymphocytic leukemia (CLL) and disease transformation was found to be safe and demonstrates a high rate of complete remission.
Read More ›
Umbralisib plus Ublituximab in Patients with Treatment-Naïve and Relapsed or Refractory CLL
ASH 2020 – CLL: Wrap-Up
The combination of umbralisib and ublituximab, referred to as U2, was well-tolerated and significantly improved progression-free survival when compared with standard of care in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL).
Read More ›
Prognostic Biomarker Testing, Treatment Patterns, and Dosing Among Patients with CLL/SLL
ASH 2020 – CLL: Wrap-Up
The informCLL registry of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can help to resolve knowledge gaps that may be identified in the evaluation and treatment of patients with CLL/SLL.
Read More ›
Ibrutinib plus Venetoclax for First-Line Treatment of CLL/SLL: Results from the CAPTIVATE Study
ASH 2020 – CLL: Wrap-Up
Primary results from the CAPTIVATE study demonstrate that fixed-duration treatment with ibrutinib plus venetoclax offers treatment-free remission for patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read More ›
Combination Ibrutinib plus Venetoclax for Relapsed/Refractory CLL: Long-Term Follow-Up Data
ASH 2020 – CLL: Wrap-Up
Combination ibrutinib plus venetoclax treatment results in sustained response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This response is sustained despite planned discontinuation in patients who had achieved minimal residual disease.
Read More ›
Clonal Dynamics After Venetoclax-Obinutuzumab Therapy in Patients with CLL
ASH 2020 – CLL: Wrap-Up
Individual clonal growth rates can be used to estimate the minimal residual disease doubling time after fixed-duration treatment. Clonal growth rates were lower after treatment with venetoclax-obinutuzumab when compared with chlorambucil-obinutuzumab.
Read More ›
Thalidomide plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocytic Leukemia
ASH 2020 – CLL: Wrap-Up
The combination regimen of thalidomide, prednisone, and methotrexate demonstrated greater efficacy than treatment with cyclosporine and prednisone in patients with large granular lymphocytic leukemia and with limited adverse events.
Read More ›
Fixed-Duration Venetoclax-Rituximab for Relapsed or Refractory CLL: Five-Year Analysis of the MURANO Study
ASH 2020 – CLL: Wrap-Up
Two-year fixed-duration treatment with venetoclax-rituximab demonstrates durable response, with a substantial proportion of patients retaining undetectable minimal residual disease 36 months after treatment cessation.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us